Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report

Shan Jiang1,2,3,4, Kay Ka-Wai Li5, Jingqi Hu1,2

  • 1Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.

Frontiers in Oncology
|February 11, 2026
PubMed

Insights

CIC-rearranged sarcoma (CRS) is a rare brain tumor lacking EWSR1 gene fusions. This case highlights diagnosis using advanced omics and methylation profiling, and its progression post-treatment.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • CIC-rearranged sarcoma (CRS) is a rare small round blue cell tumor defined by CIC gene rearrangement, distinct from Ewing's sarcoma.
  • CRS is now classified as a mesenchymal non-meningeal epithelial tumor under the 2021 WHO CNS tumor classification.
  • Primary intracranial CIC::DUX4 rearrangement sarcoma is exceptionally rare, with limited treatment options and poor prognosis.